As you can imagine, it has been a really challenging year for CPDD as an organization. We were busy planning the 2020 CPDD Annual Meeting, originally scheduled for June 20-24th in Hollywood, Florida, when the corona virus (COVID-19) public health crisis emerged. The corona virus pandemic has affected every part of our lives. My heart goes out to those who are facing loss of friends and family related to the virus or feeling isolated and alone. It seems we are all adapting as best we can by acquiring skills in video conferencing and remote learning to hold virtual meetings and classes in our kitchens and living rooms. Many are also juggling caring for children or elderly family.

The health and well-being of our meeting attendees is of utmost concern for CPDD. CPDD leadership has struggled with how to best handle the upcoming CPDD annual meeting. As detailed in our prior email to members (here) CPDD had to address legal contracts with hotels and vendors for our annual meeting, and consider the financial health of CPDD as a not-for-profit organization. After months of negotiation, CPDD successfully negotiated cancellation of the in-person meeting in Florida and cancellation of the hotel contracts under the Force Majeure (no fault to either party) condition, and rapidly shifted to a full virtual meeting platform. I want to thank the Program Committee and its Chair, Kelly Dunn, who tirelessly reworked the program to optimize materials for an online meeting platform, and developed unique opportunities for virtual networking and question/answer periods. The meeting even includes sessions for CME credits. In short, I have been so impressed by the new virtual program and the work of this committee. Some positive changes will come out of this pandemic planning. I can envision CPDD retaining this new strategy of recording sessions and offering some virtual content as an option for future meetings. If you have questions or feedback, CPDD has a single email address for contacting all CPDD management staff (Info@CPDD.org).

Follow and tag us on twitter (@CPDDorg). The Communications Committee co-chaired by Erin Winstanley and Qiana Brown has spearheaded a competition (with prizes) based on your tweets!

In addition to building a virtual meeting platform, CPDD had to determine how to handle the travel awards. CPDD receives an NIH/NIDA R13 grant ($95k) for annual CPDD meeting. The majority of funds (~80%) cover the various Travels Awards that CPDD and NIDA offer to students and young investigators to attend and participate in the conference. After discussion with NIDA program staff, CPDD determined deferring awards was not optimal. First, the NIH/NIDA grant is for the 2020 Annual meeting which is currently under a no-cost extension.
Second, the CPDD Travel awards are highly competitive and prestigious awards that are important to young investigators for careers advancement. The selected awardees for the 2020 meeting deserve to be honored and to have a venue to present their research. Third, we are confident that CPDD can provide a strong virtual program and offer unique networking activities for them at these critical junctures in their careers. After discussion with NIDA, CPDD leadership developed a plan to provide “travel awards” to the virtual meeting where there is no travel to reimburse. CPDD also recognized that many Universities are facing the financial losses due to the pandemic and some faculty and students have lost jobs or had reductions in salaries and benefits.

We worked with NIDA to reallocate funds to allow the following:
• Reduced meeting registration fees by 50% and extended the early bird rate deadline
• Increased the number of CPDD Early Career Awards
• Increased the number of Primm-Singleton Awards for underrepresented populations
• Increased the number of NIDA Director’s Awards
• Increased the number of NIDA Women & Gender Awards
• Increased the number of CPDD International Awards
• Increased participation by international attendees by providing co-funding of registration with NIDA for 70 presenters at the NIDA’s International Poster session
• CPDD assumed AV costs and organization for the virtual meeting for NIDA’s International Forum Poster session

I want to acknowledge the hard work of the Travel Awards Committee led by Co-chairs Ryan Vandrey and Leslie Lundahl who coordinated the review and selection of awardees from the hundreds of applications for the CPDD and NIDA travel awards. I also want to thank the URPOP committee (Chair Sherecce Fields), the FORCE Awards Committee and the International Committee (Chair Francesca Filbey) for their role in the Primm-Singleton Awards and CPDD International travel awards. Please join me in thanking them for their effort.

While the pandemic has eclipsed all other 2020 events, I do want to make you aware of other changes at CPDD. We have completed our transition to management of the CPDD office and annual meeting planning to the Parthenon Management Group (PMG). The CPDD office at Temple University in Philadelphia, which was active for over 30 years, closed on January 31, 2020. This was a sad event even though we were excited to have PMG take on management of our growing organization. The transition was smooth and seamless due to the continued dedication and grace of the CPDD Executive Officer, Loretta Finnegan and the Director of the CPDD Executive Office, Ellen Geller and the high level of professionalism and competence of the PMG team (Sarah Timm, the PMG Executive Officer and Lindsay Snyder, the Director of Client Operations).
We recently welcomed a new PMG member, Jesse Howard, who is the new CPDD program manager. The PMG team has been indispensable helping CPDD successfully weather the complexities of our annual meeting and contract negotiations during this pandemic. Many, many thanks to our Executive Officer Loretta Finnegan and our Director of the Executive Office Ellen Geller who continue to serve as consultants through this year’s meeting and continue to provide their considerable expertise and passion for CPDD. Don’t forget to attend sessions honoring them during the event.

I also want to thank our Past-President Meg Haney and Rules Chair Charles Gorodetzky for tackling the task of revising language in our Bylaws to accommodate management of our organization by PMG. This was a huge task. I am pleased to inform you that the revised Bylaws were approved by the Board and are available for viewing on the website. Over the last year, I greatly appreciated the team effort of the CPDD Executive Committee Members President-Elect Stacey Sigmon, Past-President Meg Haney, Treasurer Jack Bergman, Public Policy Officer Sandra Comer, CPDD Executive Officer Loretta Finnegan and the CPDD Executive Office Director Ellen Geller. In weekly meetings all of these people have worked endlessly for CPDD as an organization and its membership.

In closing, I greatly appreciate the CPDD officers, Board of Directors, and Committee members who are unpaid volunteers who donate their time and professional effort in support of CPDD. Your contributions in this difficult year are valued. I am grateful beyond words to our members and all those who serve CPDD. Please continue to support CPDD as an organization by paying your dues. While CPDD is largely a volunteer scientific organization, CPDD has paid staff and costs associated with managing the organization, website, and our annual meetings. We need your support and value your participation!

As we go forward, I am sure we will continue to face new challenges. We will get through this together. Thank you for the opportunity to serve as President of CPDD.

Elise Weerts, PhD
President, CPDD
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter From the President</td>
<td>2</td>
</tr>
<tr>
<td>CPDD Board of Directors</td>
<td>6</td>
</tr>
<tr>
<td>2020 Scientific Program Committee</td>
<td>7</td>
</tr>
<tr>
<td>2020 Virtual Meeting Scavenger Hunt</td>
<td>8</td>
</tr>
<tr>
<td>2020 Virtual Meeting Twitter Competition and Exhibitor</td>
<td>9</td>
</tr>
<tr>
<td>General Information</td>
<td>10</td>
</tr>
<tr>
<td>Conference Speakers</td>
<td>11</td>
</tr>
<tr>
<td>Continuing Education Credits &amp; Meeting Evaluation Information</td>
<td>17</td>
</tr>
<tr>
<td>2020 CPDD Award Winners</td>
<td>18</td>
</tr>
<tr>
<td>Schedule At A Glace</td>
<td>24</td>
</tr>
<tr>
<td>Presentation Information</td>
<td>28</td>
</tr>
<tr>
<td>2020 CPDD Travel Award Winners</td>
<td>29</td>
</tr>
<tr>
<td>Meeting Sponsors, Exhibitor &amp; Grants</td>
<td>31</td>
</tr>
<tr>
<td>In Memoriam</td>
<td>32</td>
</tr>
<tr>
<td>2020 CPDD Donors</td>
<td>34</td>
</tr>
<tr>
<td>Save The Date</td>
<td>35</td>
</tr>
</tbody>
</table>

**KEEP YOUR EYES ON THE ICONS**

Be on the look out for the following icons through the CPDD Scientific Virtual Meeting:

**Travel Awards**

- CPDD Travel Award Winner
- FORCE Travel Award Winner
- Holtzman Travel Award Winner
- International Travel Award Winner
- NIDA Directors Travel Award Winner
- NIDA Women & Sex/Gender Travel Award Winner
- Pirm-Singleton Travel Award Winner
2020 CPDD BOARD OF DIRECTORS

President
Elise Weerts, PhD
*Johns Hopkins University School of Medicine*

Past President
Margaret Haney, PhD
*Columbia University Irving Medical Center*

President Elect
Stacey Sigmon, PhD
*University of Vermont*

Treasurer
Jack Bergman, PhD
*McLean Hospital / Harvard Med School*

Executive Officer
Loretta Finnegan, MD
*Perinatal Addiction & Women’s Health*

Public Policy Officer
Sandra D. Comer, PhD
*Columbia University and NYSPI*

Director, Executive Office
Ellen B. Geller, MA
*Lewis Katz School of Medicine at Temple University*

Board Members
Ziva Cooper, PhD
*UCLA Cannabis Research Initiative*

Deborah S. Hasin, PhD
*Columbia University*

F. Ivy Carroll, PhD

RTI International

Amy Janes, PhD
*McLean Hospital, Harvard Medical School*

Jermaine Jones, PhD
*Columbia University Vagelos College of Physicians and Surgeons*

Frances R. Levin, MD
*Columbia University and NYSPI*

Wendy Lynch, PhD
*University of Virginia*

Geoffrey Mumford, PhD
*American Psychological Association*

Beatriz Rocha, MD, PhD
*Covance*

Mark Smith, PhD
*Davidson College*

William Stoops, PhD
*University of Kentucky*

Dace Svikis, PhD
*Virginia Commonwealth University*

Erin Winstanley, PhD
*West Virginia University*
CPDD LEADERSHIP

2020 SCIENTIFIC VIRTUAL MEETING

2020 SCIENTIFIC PROGRAM COMMITTEE

CHAIR
Kelly Dunn, Ph.D.
Johns Hopkins University School of Medicine

Matthew Banks, Ph.D., Pharm.D.
Virginia Commonwealth University

Gregory Collins, Ph.D.
University of Texas Health Science Center

Kevin Freeman, Ph.D.
University of Mississippi Medical Center

Diann Gaalema, Ph.D.
University of Vermont

Cassie Gipson-Reichardt, PH.D.
University of Kentucky

Jillian Hardee, Ph.D.
University of Michigan

Brian Kiluk, Ph.D.
Yale University School of Medicine

McLean Hospital, Harvard Medical School

Sterling McPherson, Ph.D.
Washington State University, Elson S. Floyd College of Medicine

Silvia Martins, M.D.
Columbia University

Maria Parker MIT, M.P.H.,M.S., Ph.D.
Indiana University

Jennifer Tidey, Ph.D.
Brown University

Reagan Wetherill, Ph.D.
University of Pennsylvania

Loretta Finnegarn, M.D. (ex officio)
Perinatal Addiction and Women's Health

Ellen Geller, M.A. (ex officio)
Lewis Katz School of Medicine at Temple University

Stephen Kohut, Ph.D.
Join Us for the Virtual Scavenger Hunt!

CPDD will be hosting a virtual scavenger hunt each day! How do you win?

During each session, a code word will be placed into the chat feature, and the combination of words from each session will make a phrase. Email the phrase at the end of each day by 7:55 PM EDT to info@cpdd.org and put ‘Scavenger Hunt’ as your subject.

Each day will have their own winner and winners will be announced in Wednesday’s closing session. You must be present to win. Good luck!

**PRIZES**

- Monday: $100 Amazon Gift Card
- Tuesday: Complimentary Membership for 2021
- Wednesday: 2-night stay at the 2021 host hotel, breakfast for 2 and 2 museum passes to be used in Montreal!
CPDD TWITTER COMPETITION

During the CPDD Virtual Scientific Meeting tweet out about the most intriguing sessions you attended, interact with fellow attendees and talk about your favorite happenings. Use #CPDD20 to be entered into the contest. Two individuals will win a $100 Amazon gift card!

1. The person who tweets the most during the conference using the hashtag.
2. One random winner

JOIN US FOR EXHIBITOR NETWORKING!

Exhibitor Hours

Monday, June 22
12:00 pm – 1:00 pm
5:00 pm – 6:00 pm

Tuesday, June 23
10:00 am – 11:00 am
5:00 pm – 6:00 pm

Wednesday, June 24
10:00 am – 11:00 am

Want to meet with a representative from USDTL?

Zoom Information will be provided on the schedule & daily email!
CREATE YOUR PERSONALIZED SCHEDULE
Login to your CPDD account to create your own personalized conference schedule! Once logged in, on the left side pane click, "My Schedule" and plan for the virtual conference by saving your favorite sessions that you don't want to miss!

JOIN THE CONVERSATION
CPDD has gone social and we invite you to join the online conversation. Please be sure to follow/like the following CPDD social media accounts:

@CPDDorg  @CPDDmembers  @CPDD

And do not forget to use the hashtag #CPDD20 if you post pictures or comments about the 2020 Scientific Virtual Meeting.

CREATING AND USING ZOOM MEETING ROOMS
Creating a Zoom Personal Meeting Room Instructions:
❖ Go to www.zoom.us
❖ Click on the blue box in the top right side of the screen “Sign-Up. It’s Free”
❖ Enter your email address
❖ Wait for the confirmation email and activate your account
❖ Login and view your profile to see your personal meeting room link.

Accessing a Zoom Personal Meeting Room Instructions:
❖ Go to www.zoom.us
❖ Click “Join a Room”
❖ Enter the meeting ID or personal room name provided

QUESTIONS
If you have questions before or during the conference, we encourage you to:
1) Use the Q&A feature to ask a question of the presenter or to contact AV support staff
2) Email info@cpdd.org with additional questions or concerns or call (615) 432-0099.
3) Stop by the Speaker Ready Room, open daily. Zoom link
4) Browse through the conference Info
George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as of January 27, 2014. He is also a Senior Investigator at the Intramural Research Program of the National Institute on Drug Abuse where he directs the Neurobiology of Addiction Laboratory in the Integrative Neurosciences Research Branch. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 750 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field, and a textbook for upper division undergraduates and graduate students called “Drugs, Addiction and the Brain.” He has mentored 11 Ph. D students and over 80 post-doctoral fellows and mentored or co-mentored 11 K99’s. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972. He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine (USA) and award of the Legion of Honor (France).
Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging and has published more than 720 peer-reviewed articles, written more than 100 book chapters and non-peer-reviewed manuscripts, and edited four books on neuroimaging for mental and addictive disorders.
Dr. Weerts is the President of CPDD and a Professor in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine, and core faculty in the Behavioral Pharmacology Research Unit (BPRU) for human laboratory research and the preclinical Division of Behavioral Biology (DBB). Her translational research program is focused on the behavioral and neurobiological mechanisms associated with drug and alcohol misuse and substance use disorders (SUD), and application of this knowledge towards development of medications.
Dr. Michael A. Taffe obtained his bachelor’s degree from The Colorado College in 1990 and went on to complete doctoral studies in Experimental Psychology at the University of California, San Diego in 1995. Following a brief postdoctoral stint in the Department of Psychiatry at UCSD, he joined The Scripps Research Institute as a post-doc and was eventually appointed to the faculty of TSRI in 2000. Dr. Taffe was recruited to join the faculty of the Department of Psychiatry at UCSD in 2019. The work of Dr. Taffe’s laboratory has been focused on the potential harms and health risks that attend both acute and chronic exposure to recreational drugs, including MDMA (“Ecstasy”), alcohol, Δ9-tetrahydrocannabinol (THC) and the designer cathinone psychostimulants (“bath salts”). The laboratory also investigates neurobiological alterations associated with prescription opioid abuse and potential new treatment strategies for Oxycontin dependence. The therapeutic development work in the laboratory extends to evaluating anti-drug vaccines for potential use against methamphetamine, oxycodone and “bath salts” abuse and dependence. Investigations with cannabidiol focus primarily on the way it modulates the behavioral effects of THC.
Dr. Yasmin Hurd is the Ward Coleman Chair of Translational Neuroscience and Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai in New York as well as the Director of the Addiction Institute within the Mount Sinai Behavioral Health System. Dr. Hurd is an internationally renowned neuroscientist whose translational research examines the neurobiology of drug abuse and related psychiatric disorders. She is highly published in the field and leads a diverse team of investigators spanning molecular biology, behavioral neuropharmacology and neuroimaging to study the human brain and complementary translational animal models. Her research exploring the neurobiological effects of cannabis and heroin has significantly shaped the field. Using multidisciplinary research approaches, her research has provided novel insights into the impact of developmental cannabis exposure and epigenetic mechanisms underlying the drug’s protracted effects into adulthood and even across generations. Dr. Hurd’s basic science research is complemented by clinical laboratory investigations evaluating the therapeutic potential of novel science-based strategies for the treatment of psychiatric disorders including opioid addiction.
Dr. Ziva Cooper is the Research Director of the UCLA Cannabis Research Initiative in the Jane and Terry Semel Institute and Associate Professor in the Department of Psychiatry. Her research involves understanding variables that influence both the therapeutic potential and adverse effects of cannabis and cannabinoids through double-blind, placebo-controlled studies. Current projects include understanding differences between men and women in their response to the abuse-related and pain-relieving effects of cannabis, the potential for cannabis constituents to reduce reliance on opioids, and therapeutic effects of cannabinoids in patient populations. Dr. Cooper served on the National Academies of Sciences Committee on the Health Effects of Cannabis that recently published a comprehensive report of the health effects of cannabis and cannabinoids. She is a Board Director for the College on Problems of Drug Dependence, an Associate Editor of The American Journal of Drug and Alcohol Abuse, and is on several Editorial Boards of journals including Cannabis and Cannabinoid Research and Neuropsychopharmacology.
Continuing Education Credits & Meeting Evaluation Information

All meeting attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CE credit for the meeting are required to complete the evaluation. This form is available online only. Evaluations will be emailed to attendees at the completion of the conference. All evaluations must be completed by July 31, 2020.

Continuing Education and Disclosures

Attendees will be eligible to receive the credit hours listed below for attending the Conference. To obtain CE credits for the conference, you must complete the post-conference meeting evaluation.

There will be a $100.00 charge for registrants to obtain CE credits. If you did not pay for the CE credits during registration, you will be prompted to do so during the evaluation process. Upon completion of the post-conference evaluation and attestation, your CE certificate will be emailed to you. Please note, this email will often go to spam. If you do not receive your certificate, please email info@cpdd.org

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The College on Problems of Drug Dependence (CPDD). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™ for for physicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists

This course is co-sponsored by Amedco and CPDD. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. Maximum of 21.75 hours.
Congratulations!

Sterling M. McPherson, PhD
Washington State University Elson S. Floyd

“This is a humbling award to receive as I and others stand on the shoulders of scientific giants who have shaped the field of addiction science long before we began our scientific careers. I hope that my being granted this award is a reminder that sound mentorship, surrounding of dedicated and caring colleagues, hard work, and perseverance are critical ingredients to being able to help shape evidence-based treatments for the some of the most vulnerable individuals in society using rigorous biomedical research. I give my thanks to my mentor, Dr. John M. Roll, and so many junior and senior colleagues and students that I get to work with and collaborate with every day.”

Dr. McPherson is an Associate Professor at the Washington State University Elson S. Floyd College of Medicine and is Executive Faculty at the Program of Excellence in Addictions Research. He completed his PhD in Experimental Psychology in 2010 and a Postdoctoral Fellowship in Psychopharmacology and Substance Abuse while working under the mentorship of Dr. John M. Roll. In 2016, he established and is lead Principal Investigator of the Analytics and PsychoPharmacology Laboratory. He has secured more than $35 million in grants/contracts as PI or Co-I from NIH and other agencies for research ranging from pharmacokinetics to health economics, including PI of a P20 Center of Excellence focused on substance abuse treatment for American Indians. He has led several treatment investigations focused on co-addiction such as alcohol and smoking, and stimulants and smoking. He currently collaborates with several industry partners on NIH-funded work on technology-enhanced addiction treatment and retention platforms. He has published over 90 peer-reviewed articles and is on the Editorial Boards of five scientific journals in the field of addiction, including Psychology of Addictive Behaviors and Addiction. Lastly, he is dedicated to international research with collaborations across seven countries in an effort to better understand and treat addiction globally.
Edward G. Singleton, M.A., Ph.D
MayaTech Corporation (Retired)

“At my first CPDD meeting 27 years ago, there weren’t many people around like me. I felt lonely, stressed out, and overwhelmed. I didn’t feel like I belonged. What I remember most is being welcomed to the “family”—this vast network of scientists and trainees, their friends, their significant others, their daughters, and their sons.

Nevertheless, it remains essential for the health of our College to encourage as many people from diverse backgrounds as possible to participate in the scientific meeting, to welcome them, and help them feel they belong. I am humbled, deeply moved, and extremely excited that the Executive Committee has honored me with this award, but when you walk among giants, you’re bound to get taller yourself.”

Edward (Ed) G. Singleton, PhD (retired) was senior clinical associate and research scientist for the MayaTech Corporation. He also had multiple appointments with NIDA’s Addiction Research Center and Intramural Research Program, including guest worker/expert consultant, staff fellow, senior fellow, visiting scientist, head of Instrumentation and Interdisciplinary Initiatives, and director of the Minority Recruitment and Training Program. Ed served in diversity initiatives for other prominent organizations such as SAMHSA’s National Historically Black College and University (HBCU) Substance Abuse and Mental Health Consortium, the U.S. Surgeon General’s Effort for Increasing Public Health Infrastructure at HBCUs, and he was appointed member of the American Psychological Association (APA) Presidential Commission on Ethnic Minority Recruitment, Retention and Training that developed APA’s initial strategic plan to diversify psychology in academe. He co-founded the Special Populations Committee of the Society for Research on Nicotine and Tobacco (SRNT) and the Underrepresented Populations Committee of CPDD. Additionally, the CPDD Primm-Singleton Minority Travel Awards Program is co-named (with Beny J. Primm, MD) in honor of service and dedication to increasing the participation of underrepresented populations in the College and accelerating the progress of racial and ethnic minorities in addiction research. Ed is an elected fellow and emeritus member of CPDD.
Linda J. Porrino, Ph.D. is currently Professor in the Department of Physiology and Pharmacology at Wake Forest School of Medicine. She received her Ph.D. in Experimental Psychology from New York University and completed postdoctoral training at the National Institute of Mental Health in the labs of Patricia Goldman-Rakic and Louis Sokoloff. She joined the faculty at Wake Forest in 1990. Her research focuses on the use of brain imaging methods to visualize the effects of chronic drug use on brain structure and function; research that has been supported continuously by NIH grants for the past 29 years. At Wake Forest she served as Chair of the Department of Physiology and Pharmacology from 2008-2019. She is the past President of the College on Problems of Drug Dependence and has served on the Advisory Council of the National Institute on Drug Abuse. She is the author of over 150 peer-reviewed publications and serves as an editor of Drug and Alcohol Dependence. She has participated in numerous study sections and continues to serve as a mentor to graduate students, residents, fellows, and faculty.
Frances R. Levin, MD
Columbia University and NYSPI

“I am honored to receive the 2020 Marian W. Fischman Lectureship Award. I was fortunate to be mentored by Marian early in my career. She also was a role model to many others. The addiction field is indebted to her, for her work and her support of young investigators.”

Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/CUIMC. Dr. Levin, working with Columbia University faculty, inaugurated the university-wide Center for Healing of Opioid and Other Substance Use Disorders: Enhancing Intervention Development and Implementation (CHosen) in 2020 and serves as one of the senior Directors. She is the Principal Investigator of a NIDA-funded T32, a K24 Mid-Career Investigator Award and several NIH grants. She is the Medical Director of two SAMHSA-supported grants, the Providers Clinical Support System and the STR-TA Opioid Response Network. Her current research interests include pharmacologic interventions for opioid, cocaine and marijuana use disorders, and treatments targeting adults with substance use disorders and attention-deficit hyperactivity disorder (ADHD). She was a long-standing member of the NIDA – Initial Review Group: Training and Career Development Subcommittee and the NIDA Interventions to Prevent and Treat Addiction (IPTA). She serves on the Board of Directors for the American Academy of Addiction Psychiatry (AAAP), CPDD, and the American Society of ADHD and Related Disorders (APSARD). She is a past President of the American Academy of Addiction Psychiatry and past Chair of the APA Council on Addiction Psychiatry.
Carol J. Boyd, PhD, MSN, FIAAN, FAAN
University of Michigan

“This is an incredibly special honor. Receiving the CPDD 2020 Mentorship Award from an organization known for its stellar mentors and scientists means the world to me. I am very grateful. I thank CPDD and those that nominated me for this meaningful recognition.”

Dr. Carol J Boyd is the current director of the Center for the Study of Drugs, Alcohol, Smoking and Health at the University of Michigan. She was the former Director of the Substance Abuse Research Center (1995-2004) and the Institute for Research on Women & Gender (2005-2011) at the University of Michigan, Ann Arbor. Dr. Boyd has been the principal investigator on extramural research with racial/ethnic minority heroin users and crack smokers (1989-1995, NIH), women cigarette smokers (1997-2000, Robert Wood Johnson Foundation), prisoners (1999-2004, Michigan Department of Corrections and Robert Wood Johnson Foundation), adolescents and college students (2003-present, NIH), and sexual minorities (2007-present, NIH). In 1999, she was the first researcher as a PI to develop a web-based survey, Student Life Survey (SLS), to be administered to a large sample of undergraduates. Dr. Boyd currently has NIH funding to study e-cigarette use among adolescents using the Population Assessment of Tobacco and Health data and Monitoring the Future data and another NIH funded study to examine the severity of substance use disorders among sexual minorities. Dr. Boyd publishes extensively in health and interdisciplinary journals including in Journal of Adolescent Health, Pediatrics, LGBT Health, and Substance Abuse.
Congratulations!

Will M. Aklin, PhD
National Institutes of Health

“My career has been devoted to treatment of individuals who suffer with substance use disorders and related problems. Whether that is through direct patient care or research administration, I have always strived to advance the understanding of new scientific knowledge to improve and develop novel behavioral treatments. I am truly honored to receive this award from an organization that upholds these same values and mission.”

Will M. Aklin, Ph.D. is director of the Behavioral Therapy Development Program within the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse. He received his Ph.D. in Clinical Psychology from the University of Maryland. Dr. Aklin’s areas of research include development of treatments targeting neurobehavioral processes (impulsivity, risk propensity); theory-derived treatments (mechanisms of behavior change); studies that integrate behavioral/pharmacological treatment, and treatment optimization through digital therapeutics (mobile, web, and other platforms). Dr. Aklin has extensive clinical research experience in behavioral and cognitive-behavioral treatment for substance use disorders (SUDs); adaptive brief interventions and adherence trials. Dr. Aklin coordinates several NIDA flagship initiatives and established collaborative partnerships with NIAAA and NCI through the Collaborative Research on Addiction at NIH (CRAN) on the development and testing of behavioral therapies for drug and alcohol use disorders. Dr. Aklin is a sought-after leader across NIH, and co-leads several NIH Common Fund initiatives, including Science of Behavior Change: User-Inspired Research to Optimize Behavior Change Interventions and Outcomes, as well as partnerships with the Food and Drug Administration (FDA) on digital therapeutics and device-based treatments for substance use disorders.
## SCHEDULE AT A GLANCE

### JUNE 22

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m. - 11:55 a.m.</td>
<td>Plenary*</td>
</tr>
<tr>
<td>12:00 p.m. - 12:55 p.m.</td>
<td>Exhibitor Hour</td>
</tr>
<tr>
<td>1:00 p.m. - 1:30 p.m.</td>
<td>Virtual Poster Q&amp;A Session I</td>
</tr>
<tr>
<td>1:30 p.m. - 2:25 p.m.</td>
<td>Virtual Networking Session Q&amp;A</td>
</tr>
<tr>
<td>2:30 p.m. - 3:30 p.m.</td>
<td>Workshop*: Navigating a Career in Addiction Science</td>
</tr>
<tr>
<td>3:30 p.m. - 4:30 p.m.</td>
<td>Late-Breaking Presentation Session I</td>
</tr>
<tr>
<td>4:30 p.m. - 5:00 p.m.</td>
<td>Virtual Networking Session Q&amp;A</td>
</tr>
<tr>
<td>5:00 p.m. - 5:55 p.m.</td>
<td>Exhibitor Hour</td>
</tr>
<tr>
<td>6:00 p.m. - 6:55 p.m.</td>
<td>Workshop*: Demystifying the NIH Peer Review Process</td>
</tr>
<tr>
<td>7:00 p.m. - 7:55 p.m.</td>
<td>Membership Workshop Session</td>
</tr>
</tbody>
</table>

### JUNE 23

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. - 9:00 a.m.</td>
<td>NIDA International Poster Q&amp;A</td>
</tr>
<tr>
<td>10:00 a.m. - 10:55 a.m.</td>
<td>Exhibitor Hour</td>
</tr>
<tr>
<td>11:00 a.m. - 11:55 a.m.</td>
<td>Workshop*: Clinical Use of Cannabinoids: Potential Promises &amp; Pitfalls</td>
</tr>
<tr>
<td>12:00 p.m. - 12:55 p.m.</td>
<td>Exhibitor Hour</td>
</tr>
<tr>
<td>1:00 p.m. - 1:30 p.m.</td>
<td>Virtual Poster Q&amp;A Session II</td>
</tr>
<tr>
<td>1:30 p.m. - 2:25 p.m.</td>
<td>Virtual Networking Session Q&amp;A</td>
</tr>
<tr>
<td>2:30 p.m. - 3:30 p.m.</td>
<td>Workshop*: The Resurgence of Illicit Stimulants in the Ongoing Substance Use Disorder Epidemic</td>
</tr>
</tbody>
</table>

---

*All times are in Eastern Daylight Time

*Indicates this session qualifies for continuing education credits.
12:00 p.m. – 12:55 p.m.
Presidential Symposium*: A Translational Discussion of the Therapeutic Potential & Adverse Consequences of Cannabinoids

1:00 p.m. – 1:30 p.m.
Virtual Networking Session Q&A

1:30 p.m. - 2:00 p.m.
Mini-Symposium*: Use of Drugs by Parents and Their Offspring

Mini-Symposium*: Immunological Approaches to the Fentanyl Epidemic

2:00 p.m. - 2:55 p.m.
Symposium: Aging and Addiction: Promoting Crosstalk Between Two Fields of Research

Workshop*: Digital Delivery of Future Thinking Interventions To Reduce Temporal Discounting and Substance Use

3:00 p.m. – 3:30 p.m.
Virtual Networking Q&A with Loretta Finnegan, MD, Executive Officer, CPDD

Virtual Networking Q&A with Ellen Geller, MA, Director, CPDD Executive Office

3:30 p.m. - 4:30 p.m.
Oral Communications II, Q&A
- Craving
- Lifecourse
- Nicotine/Tobacco
- Perinatal
- Policy
- Social Factors
- Stimulant/Medication Development
- Treatment from ED/Hospital

Late-Breaking Presentation Session II

4:30 p.m. - 5:00 p.m.
Late-Breaking Q&A Session II

Virtual Networking Session Q&A

5:00 p.m. - 5:55 p.m.
Animal Forum: Gaining Perspective on Nonhuman Animal Models of Substance Use Disorders: Insights from NIDA’s Recent RFI

Exhibitor Hour

6:00 p.m. - 6:55 p.m.
Policy Forum*: Policy Forum: Annual Update From Capitol Hill and a Panel on Advances in Hallucinogen Research

Workshop*: Missing Data Matters: Substance Use Disorder Trials

7:00 p.m. - 7:55 p.m.
Workshop*: Design and Analysis Workshop

Workshop: Community Engagement Strategies for Addressing Substance Use in Racial/Ethnic Communities

All times are in Eastern Daylight Time
*Indicates this session qualifies for continuing education credits.
JUNE 24

10:00 a.m. - 10:55 a.m.
Exhibitor Hour

Virtual Poster Q&A Session III
• Behavioral Economics
• Cannabis
• Commentary/Program Description/Review
• Comorbidities, Medical
• Comorbidities, Psychiatric
• Infectious Disease
• Opioids
• Polysubstance
• Stress

11:00 a.m. - 11:55 a.m.
Symposium*: Estrogen-Cannabinoid Interactions Both in Preclinical and Clinical Research

Symposium*: Innovative Solutions to Expand Treatment for Opioid Use Disorder in Rural Communities

12:00 p.m. - 12:55 p.m.
Symposium*: Advancing Polysubstance Research With Translational Approach

Symposium*: fMRI Drug Cue Reactivity (FDCR) as a Drug Development Tool (DDT) for Addiction Medicine: From Clinical and Experimental Evidence to FDA Standards

12:55 p.m. - 1:30 p.m.
Virtual Networking Session Q&A

Mini-Symposium*: Calling Tech Support: Technology-Facilitated Interventions to Reduce Substance Use and Advance HIV Prevention and Care

Mini-Symposium*: Catalyst for Change: Novel Treatments in Substance Use Disorder

2:00 p.m. - 2:55 p.m.
Workshop*: Exploring the Clinical Utility of Biomarkers to Personalize Treatment Services for Tobacco Use Disorder

Symposium*: Stepping On or Stepping Off?: Recent Findings on Cannabis and Opioids in Multiple Settings

3:00 p.m. - 3:30 p.m.
Mini-Symposium*: Artificial Intelligence Technologies to Enable Drug Development for Substance Use Disorders

Mini-Symposium*: Substance Use Behaviors Among Sexual and Gender Minority Individuals: A Multi-Level and Mixed-Methods Approach

1:30 p.m. - 2:00 p.m.
JUNE 24

3:30 p.m. - 4:30 p.m.
Town Hall Forum: Getting Your Investigational New Drug (IND) and Investigational Device Exemption (IDE) Applications Approved by the Food and Drug Administration (FDA)

Oral Communications III, Q&A
- Abuse Potential
- Endocarditis
- HIV/HCV/Stigma
- Hormone
- Nonfatal Overdose
- Opioid Medication Development
- Opioid Treatment
- Pain
- Phenotyping/Affect/Self Regulation
- Polysubstance Abuse

4:30 p.m. - 5:00 p.m.
Virtual Networking Session Q&A

5:00 p.m. - 5:55 p.m.
Workshop*: Technological Advancements of Human Cell-Based Studies for SUD Research

Workshop*: 26th Annual Contingency Management Working Group

6:00 p.m. - 6:55 p.m.
Workshop: Epidemiology and Public Health Research Methods

Workshop*: Evidence Based Selection of Patients and Outcomes in Clinical Trials: Towards an FDA Approved Medication for Stimulant Use Disorder

7:00 p.m. – 7:55 p.m.
CPDD Business Meeting (Open to CPDD Members Only)

7:55 p.m. – 8:00 p.m.
Final Wrap-Up & Prize Giveaway

All times are in Eastern Daylight Time
*Indicates this session qualifies for continuing education credits.
The 2020 Scientific Meeting has transitioned to a VIRTUAL experience. All the science sessions will be hosted on a Zoom platform and will run June 22-24, 2020, as originally scheduled. All session links will be shared with presenters and attendees before the conference launches. Please note that sessions will be recorded and remain live in a conference library for 30 days in case you are not able to attend the conference on the dates scheduled.

If you have questions before or during the conference, we encourage you to:
1) Use the Q&A feature to ask a question of the presenter or to contact AV support staff
2) Email info@cpdd.org with additional questions or concerns. Calling the CPDD Executive Office is not advised as the response time may be delayed during the conference.
3) Stop by the Speaker Ready Room, open daily. Zoom link

All poster presentations will be available in the e-poster gallery for conference attendees to view at their convenience. Click here to access the gallery. Poster presenters can be contacted during their assigned session using the “Join Online Meeting” link. This link will bring you to the presenter’s personal Zoom meeting room or email address depending on which they selected as their preferred communication method. Authors are asked to be in attendance during the poster session to answer questions about your poster.

**POSTER SESSION HOURS**
- **Monday, June 22, 2020:**
  - 12:00 PM – 12:55 PM EDT
- **Tuesday, June 23, 2020:**
  - 8:00 AM – 9:00 AM (NIDA International) / 10:00 AM – 10:55 AM EDT
- **Wednesday, June 24, 2020:**
  - 10:00 AM – 10:55 AM EDT

**NETWORKING**

Networking is an essential part of the 2020 CPDD Virtual Scientific Meeting. Please be sure to schedule collaboratory meetings and discussions throughout the conference by inviting attendees to join you in a personal Zoom meeting room.

**Zoom Personal Meeting Room:**
- Go to [www.zoom.us](http://www.zoom.us)
- Click on the blue box in the top right side of the screen “Sign-Up. It’s Free”
- Enter your email address
- Wait for the confirmation email and activate your account
- Login and view your profile to see your personal meeting room link.
CPDD TRAVEL AWARD WINNERS

STEPHEN G. HOLTZMAN TRAVEL AWARD FOR PRECLINICAL INVESTIGATORS
Drew Townsend, Ph.D.

CPDD INTERNATIONAL AWARD
Joao Mauricio Castaldelli-Maia, M.D., Ph.D.
Matiwos Soboka Daba, M.Sc, Assistant Professor
Oyapero Afolabi, BDS, MPH., FMCDs
Vitor Soares Tardelli, M.D., M.S.
Suzaily Wahab, M.D., DR(PSYCH)

CPDD PRIMM-SINGLETON MINORITY TRAVEL AWARD
Naomi Dambreville, Ph.D.
Fernando B. de Moura, Ph.D.
Mariely Hernandez, M.A.
Danielle S. Jackson M.D., M.P.H
Luisa Kcomt, Ph.D., M.S.W, B.S.W
Natasha Ludwig-Barron, Ph.D. (c), M.P.H
Maylen Perez Diaz, Ph.D.
Simon Sandh, M.P.H
Trey B. Warren, M.P.H Candidate
Sitara Weerakoon, B.A., M.P.H

F.O.R.C.E. TRAVEL AWARD
Kathryn Hawk, M.D., M.H.S
Ashly E Jordan, Ph.D., M.P.H
Noa Krawczyk, Ph.D.

CPDD TRAVEL AWARD FOR EARLY CAREER INVESTIGATORS
Olufemi Ajumobi, M.D., M.P.H
Rachel Altschuler, Ph.D.
Erin M. Anderson Goodell, Ph.D., Sc.M
Anahita Bassir Nia, M.D.
Gayatri Bhatia, M.D.
Kathryn Biernacki, Ph.D.
Stevie C. Britch, Ph.D.
Amanda Bunting, Ph.D.
Ginny Carter, Ph.D., RN
Felipe Castillo, M.D.
Sarah Cercone Heavey, Ph.D., M.P.H
Thomas Chao, M.A.
Tianzhen Chen, M.D.
Vivian Chiu, Ph.D. candidate
William H. Craft, B.S.
Kathleen Isabel Crum, Ph.D.
Megan E. Curtis, Ph.D.
Mary Kathryn (Kate) Dahlgren, Ph.D.
Zheng Dai, Ph.D.
Amelia Dunn, Ph.D.
Jonathan Feelemyer, M.S.
Alan N. Francis, Ph.D.
Erik J. Garcia, Ph.D.
Stephanie Glegg, OT, Ph.D.
Leah Hamilton, Ph.D.
Penelope L. Hill, BHS, MSc, GD Dev Stud, Ph.D. candidate
Laura Hughes, B.BiomedSc(Hons) GDipPsych
Charlotte Kervran, Ph.D.
Simeon D. Kimmel, M.D., M.A.
Elizabeth Kinnard, B.A., M.S.
Sukhpreet Klaire, M.D., CCFP
Elias Klemperer, Ph.D.
Emanuel Krebs, M.A.
Soeren Kuitunen-Paul, Dipl.-Psych.
Jessica A. Kulak, Ph.D., M.P.H
Laura Lambert, Ph.D. student
Danni Lanaway, Ph.D.
Antoine Lebeaut, M.A.
Juhan Lee (John), B.A.
Anna Liley, M.S.
Lewei (Allison) Lin, M.D., M.S.
Jingxin Liu, M.P.H
Shawnta L. Lloyd, M.P.H
Laura MacKinnon, M.D.
Caitlin E. Martin, M.D., M.P.H
Caravella McCuistian, Ph.D.
Alexandra Mellis, Ph.D.
Christina R. Merritt, B.S.
Barrett Wallace Montgomery, B.S.
Benjamin Oldfield, M.D.
## CPDD TRAVEL AWARD WINNERS

### CPDD TRAVEL AWARD FOR EARLY CAREER INVESTIGATORS (CONT)

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandra N. Palmisano</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Kelly Peck</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Rajiv Radhakrishnan</td>
<td>M.B.B.S, M.D.</td>
</tr>
<tr>
<td>Claudia Rafful</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Timothy Regan</td>
<td>M.A.</td>
</tr>
<tr>
<td>Jennie Ryan</td>
<td>Ph.D., CPNP-AC</td>
</tr>
<tr>
<td>Stephen Scroggins</td>
<td>M.Sc.</td>
</tr>
<tr>
<td>Kristin Serowik</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Justin M. Shepherd</td>
<td>M.A.</td>
</tr>
<tr>
<td>Dennis Sholler</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Cho-Hee Shrader</td>
<td>M.P.H.</td>
</tr>
<tr>
<td>Chang (April) Shu</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Kelsey A. Simpson</td>
<td>M.A.</td>
</tr>
<tr>
<td>Lia J. Smith</td>
<td>M.A., L.P.A.</td>
</tr>
<tr>
<td>Aaron P. Smith</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Michael J. Sofis</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Philip Spechler</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Nichole E. Stetten</td>
<td>Ph.D., M.P.H, C.P.H.</td>
</tr>
<tr>
<td>D.W. Svenson</td>
<td>B.A.</td>
</tr>
<tr>
<td>Devin C. Tomlinson</td>
<td>B.S.</td>
</tr>
<tr>
<td>Aaron Tryhus</td>
<td>B.S.</td>
</tr>
<tr>
<td>Alyssa Vanderziel</td>
<td>M.S.</td>
</tr>
<tr>
<td>Adam Viera</td>
<td>M.P.H.</td>
</tr>
<tr>
<td>An Ye</td>
<td>Ph.D.</td>
</tr>
</tbody>
</table>

### NIDA Women & Sex/Gender Junior Investigator Travel Award

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shalini Arunogiri</td>
<td>M.B.B.S (Hons), Ph.D.</td>
</tr>
<tr>
<td>MPsychiatry</td>
<td>M.Sc., FRANZCP Cert Addiction Psychiatry</td>
</tr>
<tr>
<td>Tara Bautista</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Emilie Bruzelius</td>
<td>M.P.H</td>
</tr>
<tr>
<td>Julien Dodu</td>
<td>B.Sc.</td>
</tr>
<tr>
<td>Michelle Doyle</td>
<td>B.S.</td>
</tr>
<tr>
<td>Daniel Farkas</td>
<td>B.S.</td>
</tr>
<tr>
<td>Jessica M. Illenberger</td>
<td>M.A.</td>
</tr>
<tr>
<td>Natalie Levy</td>
<td>M.P.H.</td>
</tr>
<tr>
<td>Elisa Pabon</td>
<td>B.S.</td>
</tr>
<tr>
<td>Maria A. Parker</td>
<td>Ph.D., M.S., M.P.H.</td>
</tr>
<tr>
<td>Anna Beth Parlier-Ahmad</td>
<td>M.S.</td>
</tr>
<tr>
<td>Shannique Richards</td>
<td>M.A.</td>
</tr>
<tr>
<td>Abigail Richison</td>
<td>M.D.</td>
</tr>
<tr>
<td>Gabriella G. N. Robinson</td>
<td>M.A.</td>
</tr>
<tr>
<td>Karl T Schmidt</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Luis E Segura</td>
<td>M.P.H, Dr.PH.</td>
</tr>
<tr>
<td>Paige M. Shaffer</td>
<td>M.P.H.</td>
</tr>
<tr>
<td>Jessica L. Sharp</td>
<td>D.Phil.</td>
</tr>
<tr>
<td>Sara Weidberg</td>
<td>Ph.D.</td>
</tr>
</tbody>
</table>

### NIDA Director’s Travel Award

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samantha Auty</td>
<td>M.S.</td>
</tr>
<tr>
<td>Sugy Choi</td>
<td>M.S.</td>
</tr>
<tr>
<td>Danielle R. Davis</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>José E. Diaz</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>David Goodman-Meza</td>
<td>M.D., M.A.S</td>
</tr>
<tr>
<td>Sarah Gutkind</td>
<td>M.S.P.H.</td>
</tr>
<tr>
<td>Scott E. Hadland</td>
<td>M.D., M.P.H, M.S.</td>
</tr>
<tr>
<td>Lindsey R Hammerslag</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Asti Jackson</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Natrina &quot;Trina&quot; John</td>
<td>M.S., Ph.D. Candidate</td>
</tr>
<tr>
<td>Shea M. Lemley</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Megan McClintick</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Tatum Oleskowicz</td>
<td>M.A., B.A.</td>
</tr>
<tr>
<td>Morgan Philbin</td>
<td>Ph.D., M.H.S</td>
</tr>
<tr>
<td>Jillian M. Rung</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Gregory L. Sahlem</td>
<td>M.D.</td>
</tr>
<tr>
<td>Kristin E. Schneider</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Chelsea L. Shover</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Nathan D. L. Smith</td>
<td>ALM</td>
</tr>
<tr>
<td>University of Florida</td>
<td>Tory Spindle, Ph.D.</td>
</tr>
<tr>
<td>Joanna M. Streck</td>
<td>Ph.D. Candidate</td>
</tr>
<tr>
<td>Justin Strickland</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Joji Suzuki</td>
<td>M.D.</td>
</tr>
<tr>
<td>Eric A. Thrailkill</td>
<td>Ph.D.</td>
</tr>
<tr>
<td>Andre B. Toussaint</td>
<td>M.A.</td>
</tr>
<tr>
<td>Noel A. Vest</td>
<td>Ph.D.</td>
</tr>
</tbody>
</table>
CPDD would like to acknowledge the generosity of the following companies whose unrestricted educational grant have contributed to the overall quality of this meeting:

**Indivior**

Funding for this conference was made possible (in part) by 5 R13 DA 013192 - 15 from the National Institute on Drug Abuse

*The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.*
In Memoriam

Louis S. Harris, Ph.D.
(1927-2019)

Dr. Louis S. Harris, former chair of The Committee on Problems of Drug Dependence and President of the College on Problems of Drug Dependence, died on Monday, June 10, 2019.

Lou was chair of the Department of Pharmacology and Toxicology at the Medical College of Virginia of Virginia Commonwealth University from 1972 to 1992. From 1979, until his retirement in 2006, he served the drug abuse community, CPDD and NIDA by leading the evaluation of the physical dependence liability testing of new opioid-like compounds. He was one of the first scholars to embrace the narcotic agonist-antagonist concept for new pain relievers and lead the development of pentazocine, the first of these drugs to make the market. Lou was presented with the Eddy Award by The College and won awards from other scholarly societies, his university and state. He and his family were very generous supporters of his university and many other worthy scholarly organizations. They provided the funds for four professorships in different schools at VCU and supported many programs in other educational institutions. He was preceded in death by his wife Ruth and is survived by his son Charles. Lou will be fondly remembered by a large number of friends throughout Richmond VA and by scholars everywhere.
In Memoriam

Eric J. Simon, Ph.D.
(1924-2020)

Two months shy of 96, passed away peacefully on Monday, March 30th at his residence in Hackensack, NJ. Born in Wiesbaden Germany, at age 14, Eric and his family were uprooted from their home in Wiesbaden, Germany, as they fled Nazi persecution in 1938. He served in the United States army during W.W.II.

Post-service, Dr. Simon began a long and distinguished career establishing himself as a scientist of worldwide renown, yet he remained forever humble. Eric lived with his wife, the love of his life, in Bergen County, NJ for 66 years. They lived in Teaneck for 54 years before moving to Hackensack 12 years ago. Eric was a Neuroscientist and headed a lab at NYU Langone Medical Center for 54 years before retiring in 2014, at the age of 90 as Professor Emeritus. As part of his many accomplishments, Dr. Simon discovered opiate receptors in the brain and coined the word Endorphin. One of Eric’s passions was skiing, which he did until he was 86. It provided many wonderful family times together. Pre-deceased by his loving wife Irene in 2017, he is survived by his adoring family: daughter Faye and her husband Len, son Martin, son Larry and his wife Lea, 4 grandchildren, 11 great-grandchildren and his brother Walter. An amazing person, brilliant man, an outstanding scientist, Eric loved his family and friends with a passion, warmth, love, generosity – like no other. He was kind to and interested in everyone. He had a zest to live, a “joie de vivre” beyond anyone we knew. He has deeply touched so many hearts. He will be remembered by so many, but his passing leaves a huge hole, at the same time that his life leaves a huge impact and presence.

A virtual graveside service will be held on Monday, April 6th at 2pm. To get the information to sign in for the service, call Gutterman and Musicant Funeral Home 800-522-0588. Please start calling 1:30pm, so that all have joined in time for the Rabi to start at 2pm. Once the Covid situation is under control, we will have an in person gathering to celebrate his life and mourn his death together. Donations in Dr. Eric Simons’ name may be made to IES Brain Research Foundation or Prostate Cancer Foundation. The Foundation address is IES Brain Research Foundation, 270 Sparta Ave., Suite 104, NJ 07871 or online at www.iesbrainresearch.org.
Thank You!

CPDD would like to give a special thank you to all of our donors. With your help, we will continue to grow and move the science community forward.

Merideth Addicott
SB Anthony
Jim Anthony
Judy Ashworth
Michael Bardo
Alan Budney
Sandra Comer
James Cook
Ziva Cooper
Kelly Dunn
Linda Dykstra
Reginald Fant
Loretta Finnegan
Charles Gorodetzky
Margaret Haney
Deborah Hasin
Jack Henningfield
Carl C. Hug, Jr.
Amy Janes
Jermaine Jones
Kyle Kampman
Gundy B. Knos
Thomas Kosten
Scott Lane
James E. Lester II
Frances Levin
Wendy Lynch
Jan S. Mees
Donald E. Mees, Jr.
Heidi Melbostad
Geoffrey Mumford
John B. Neeld, Jr.
Marc Potenza
Sidney Schnoll
Stacey Sigmon
Mark Smith
William Stoops
Yung-Fong Sung-Holtzman
Dace Svikis
Jennifer Tidey
D. Andrew Tompkins
Patricio Viera Perez
Elise Weerts
Erin Winstanley
George Woody
SAVE THE DATE

MONTREAL, QUEBEC

JUNE 19-23, 2021